Diabetes Pen Market Research Report- Forecast Till 2027

Diabetes Pen Market Information: By Product (Insulin Pens And Insulin Pen Needle), Usage (Reusable Pens And Disposable Pens), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Sales, And Diabetes Clinics) - Forecast Till 2027

ID: MRFR/MED/0121-HCR | February 2021 | Region: Global | 80 pages

Diabetes Pen Market Scenario


Insulin is a hormone produced by the pancreas.  A diabetes pen is used to inject insulin for the treatment of diabetes. It is composed of an insulin cartridge (integrated or bought separately) and a dial to measure the dose, and is used with disposable pen needles to deliver the dose. Diabetes is a major chronic disease across the globe. Changing lifestyle, high intake of carbohydrates and sugar, and obesity are major factors elevating the prevalence of the disease. Increasing prevalence of diabetes and obesity and growing demand for diabetes pen drive the diabetes pen global market.


The diabetes pen global market is expected to grow at a CAGR of approximately 8.45% during the forecast period 2017-2023.


 Figure 1: Global Diabetes Pen Market by Region, 2016 (%) Global Diabetes Pen Market


Segments

The diabetes pen market is segmented on the basis of product, which includes insulin pens and insulin pen needles. On the basis of usage, the diabetes pen global market is segmented into reusable pens and disposable pens. On the basis of distribution channel, the diabetes pen market is segmented into hospital pharmacy, retail pharmacy, online sales, and diabetes clinics.

Key Players

Some of the key players in diabetes pen global market: AstraZeneca (U.K), Teruma Medical Corporation (Japan), Greinier Bio One International GmBH (U.S.), F. Hoffman La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Bayer Cropscience Ltd. (Germany), and HTL STREFA SA (Poland)

Figure 2: Market Synopsis
Global Diabetes Pen Market-
Regional Analysis 
The diabetes pen market consists of four regions: Americas, Europe, Asia Pacific and The Middle East & Africa. North America is the largest diabetes pen market due to large diabetic population and better awareness and reimbursement policy for diabetes management. Additionally, continuous technological advancements in diabetes pen and increasing research and development practices drive this market in North America.


Europe is the second-largest market for diabetes pen which is expected to grow at a CAGR of 1.05% from 2017 to 2023. Extensive use of diabetes pen is been found is UK is compared to other European nations. According to the World Health Organization, nearly 60 million people with diabetes in the European Region and the prevalence is higher among people aging 25 years and above.


Asia Pacific is expected to be the fastest growing diabetes pen market over the review period. Evolving healthcare infrastructure, improving awareness, large patient pool, and growing healthcare expenditure drive the Asia Pacific diabetes pen market. Furthermore, new product launch and favorable regulations speed up the growth of diabetes pen industry in Asia Pacific. India, Japan and China is expected to be the emerging and fastest growing diabetes pen global market. India is known as the hub of diabetes across the world. India is experiencing growing demand for diabetes pens due to rising geriatric population with diabetes and irregular changes in sugar levels.  Majority of people face the problem of obesity and other lifestyle diseases, which act as risk factors for diabete, which boost the demand for diabetes pen.


In Middle East & Africa will witness steady growth due to growing awareness regarding lifestyle diseases and preventive measures to tackle elevated sugar levels Africa.


Intended Audience



  • Diabetes Pen Suppliers

  • Diabetes Pen manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.45% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Usage, Distribution Channels
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca (U.K), Teruma Medical Corporation (Japan), Greinier Bio One International GmBH (U.S.), F. Hoffman La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Bayer Cropscience Ltd. (Germany), and HTL STREFA SA (Poland)
  Key Market Opportunities

  • Changing lifestyle
  • High intake of carbohydrates and sugar, and obesity
  •   Key Market Drivers

  • Increasing prevalence of diabetes and obesity
  • Growing demand for diabetes pen


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The diabetes pen market is expected to grow at a CAGR of 8.45% by 2023

    The players are Teruma Medical Corporation (Japan), AstraZeneca (U.K), F. Hoffman La Roche AG (Switzerland), Greinier Bio One International GmBH (U.S.), Bayer Cropscience Ltd. (Germany), Becton, Dickinson, and Company (U.S.), and HTL STREFA SA (Poland).

    The distribution channels are online sales, retail pharmacy, hospital pharmacy, and diabetes clinics.

    North America is leading the market with maximum market share.

    The Asia Pacific is showing signs of growth with the fastest speed.

    BRIEF TOC

    1. Report Prologue

    2. Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    2.3 Market Structure

    2.4. Market Segmentation

    3. Research Methodology

    3.1 Research Process

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    3.5 Forecast Model

    4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Mega Trends

    4.5 Macroeconomic Indicators

    5. Market Factor Analysis

    5.1 Value Chain Analysis

    5.2 Porters Five Forces

    5.3 demand & supply: gap analysis

    5.4 Pricing Analysis

    5.5 Investment Opportunity Analysis

    5.6 Merger and Acquisition Landscape

    5.7 UP-Coming trends in Diabetes Pen market

    5.7.1 Market trends

    5.7.2 Technological trends

    6. Europe Diabetes Pen Market by Product

    6.1 Introduction

    6.2 Insulin Pens

    6.3 Insulin Pen Needle

    7. Europe Diabetes Pen Market by Usage

    7.1 Introduction

    7.2 Reusable Pens

    7.3 Disposable Pens

    8. Europe Diabetes Pen Market by Distribution Channel

    8.1 Introduction

    8.2 Hospital Pharmacy

    8.3 Retail Pharmacy

    8.4 Online Sales

    8.5 Diabetes Clinics

    9. Europe Diabetes Pen Market by Region

    9.1 Introduction

    9.2 Americas

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 UK

    9.3.1.3 France

    9.3.1.4 Italy

    9.3.1.5 Spain

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Republic of Korea

    9.4.5 Australia

    9.4.6 Rest of Asia Pacific

    9.5 Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Qatar

    9.5.5 Kuwait

    9.5.6 Rest of Middle East & Africa

    10 Competitive Landscape

    11 Company Profile

    11.1 Teruma Medical Corporation

    11.1.1 Overview

    11.1.2 Product/Business Segment Overview

    11.1.3 Financial Updates

    11.1.4 Key Developments

    11.2 Greinier Bio One International GmBH

    11.2.1 Overview

    11.2.2 Product/Business Segment Overview

    11.2.3 Financial Updates

    11.2.4 Key Developments

    11.3 F. Hoffman La Roche AG

    11.3.1 Overview

    11.3.2 Product/Business Segment Overview

    11.3.3 Financial Updates

    11.3.4 Key Developments

    11.4 Becton, Dickinson and Company

    11.4.1 Overview

    11.4.2 Product/Business Segment Overview

    11.4.3 Financial Updates

    11.4.4 Key Developments

    11.5 Bayer Cropscience Ltd.

    11.5.1 Overview

    11.5.2 Product/Business Segment Overview

    11.5.3 Financial Updates

    11.5.4 Key Developments

    11.6 HTL STREFA SA

    11.6.1 Overview

    11.6.2 Product/Business Segment Overview

    11.6.3 Financial Updates

    11.6.4 Key Developments

    11.7 Astrazeneca

    11.7.1 Overview

    11.7.2 Product/Business Segment Overview

    11.7.3 Financial Updates

    11.7.4 Key Developments

    11.8 Others

    12 Conclusion

    12.1 Key Findings

    12.1.1 From CEO`s Viewpoint

    12.1.2 Unmet Needs of the Market

    12.2 Key Companies to Watch

    12.3 Prediction of Medical Device Industry

    13 Appendix